Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Barry Rockx¹*, Thijs Kuiken¹, Sander Herfst¹, Theo Bestebroer¹, Mart M. Lamers³, Bas B. Oude Munnink¹, Dennis de Meulder¹, Geert van Amerongen³, Judith van den Brand¹†, Nisreen M. A. Okba¹, Debby Schipper¹, Peter van Run¹, Lonneke Leijten¹, Reina Sikkema¹, Ernst Verschoor³, Babs Verstrepen³, Willy Bogers³, Jan Langermans⁴, Christian Drosten⁶, Martje Fentener van Vlissingen⁷, Ron Fouchier¹, Rik de Swart¹, Marion Koopmans¹, Bart L. Haagmans¹*

¹Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands. ²Viroclinics Xplore, Schaijk, Netherlands. ³Department of Virology, Biomedical Primate Research Centre, Rijswijk, Netherlands. ⁴Animal Science Department, Biomedical Primate Research Centre, Rijswijk, Netherlands. ⁵Population Health Sciences, Unit Animals in Science and Society, Faculty of Veterinary Medicine, Utrecht University, Netherlands. ⁶Institute of Virology, Charité-Universitätsmedizin, Berlin, Germany. ⁷Erasmus Laboratory Animal Science Center, Erasmus University Medical Center, Rotterdam, Netherlands.

*Corresponding author. E-mail: b.rockx@erasmusmc.nl (B.R.); b.haagmans@erasmusmc.nl (B.L.H.)
†Present address: Division of Pathology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands

The current pandemic coronavirus, SARS-CoV-2, was recently identified in patients with an acute respiratory syndrome, COVID-19. To compare its pathogenesis with that of previously emerging coronaviruses, we inoculated cynomolgus macaques with SARS-CoV-2 or MERS-CoV and compared the pathology and virology with historical reports of SARS-CoV infections. In SARS-CoV-infected macaques, virus was excreted from nose and throat in the absence of clinical signs, and detected in type I and II pneumocytes in foci of diffuse alveolar damage and in ciliated epithelial cells of nasal, bronchial, and bronchiolar mucosae. In SARS-CoV-infection, lung lesions were typically more severe, while they were milder in MERS-CoV infection, where virus was detected mainly in type II pneumocytes. These data show that SARS-CoV-2 causes COVID-19-like disease in macaques, and provides a new model to test preventive and therapeutic strategies.

Following the first reports of an outbreak of an acute respiratory syndrome in China in December 2019, a novel coronavirus, SARS-CoV-2, was identified (¹, ²). As of March 14, 2020, over 140,000 cases were reported worldwide with over 5,400 deaths, surpassing the combined number of cases and deaths of two previously emerging coronaviruses, SARS-CoV and MERS-CoV (³). The disease caused by this virus, COVID-19, is characterized by a range of symptoms, including fever, cough, dyspnoea and myalgia in most cases (²). In severe cases, bilateral lung involvement with ground-glass opacity is the most common chest computed tomography (CT) finding (⁴). Similarly to the 2002/2003 outbreak of SARS, the severity of COVID-19 disease is associated with increased age and/or a comorbidity, although severe disease is not limited to these risk groups (⁵). However, despite the large number of cases and deaths, limited information is available on the pathogenesis of this virus infection. Two reports on the histological examination of the lungs of three patients showed bilateral diffuse alveolar damage (DAD), pulmonary edema and hyaline membrane formation, indicative of acute respiratory distress syndrome (ARDS), as well as characteristic syncytial cells in the alveolar lumen (⁶, ⁷), similar to findings during the 2002/2003 outbreak of SARS-CoV (⁸). The pathogenesis of SARS-CoV infection was previously studied in a non-human primate model (cynomolgus macaques) where aged animals were more likely to develop disease (⁹–¹³). In the current study, SARS-CoV-2 infection was characterized in the same animal model and compared with infection with MERS-CoV and historical data on SARS-CoV (⁹, ¹⁰, ¹²).

First, two groups of four cynomolgus macaques (both young adult (young), 4-5 years of age; and old adult (aged), 15-20 years of age) were inoculated by a combined intratracheal (IT) and intranasal (IN) route with a SARS-CoV-2 strain from a German traveler returning from China. No overt clinical signs were observed in any of the infected animals, except for a serous nasal discharge in one aged animal on day 14 post inoculation (p.i.). No significant weight loss was observed in any of the animals during the study. By day 14 p.i. all remaining animals seroconverted as revealed by the presence of SARS-CoV-2 specific antibodies against the virus S1 domain and nucleocapsid proteins in their sera (Fig. S1).

As a measure of virus shedding, nasal, throat and rectal swabs were assayed for virus by RT-qPCR and virus culture. In nasal swabs, detection of SARS-CoV-2 RNA peaked by day 2 p.i. in young animals, by day 4 p.i. in aged animals, was detected up to at least day 8 p.i. in two out of four animals and up to day 21 p.i. in one out of four animals (Fig. 1A). Overall, higher levels of SARS-CoV-2 RNA were detected in nasal
swabs of aged animals compared with young animals. SARS-CoV-2 RNA detection in throat swabs peaked at day 1 p.i. in young and day 4 p.i. in aged animals and decreased more rapidly over time by comparison with the nasal swabs, but could still be detected intermittently up to day 10 p.i. (Fig. 1B). Low levels of infectious virus were cultured from throat and nasal swabs up to day 2 and 4, respectively (Table S1). In support of virus shedding by these animals, environmental sampling was performed to determine potential contamination of surfaces. Environmental sampling indicated the presence of low levels of SARS-CoV-2 RNA on surfaces through both direct contact (hands) and indirect contamination within the isolator (Table S2). SARS-CoV-2 RNA was only detected in a rectal swab from one animal on day 14 p.i. and no viral RNA was detected in whole blood at any time point throughout the study.

On autopsy of four macaques on day 4 p.i., two had foci of pulmonary consolidation in the lungs (Fig. 2A). One animal (aged: 17 years) showed consolidation in the right middle lobe, representing less than 5% of the lung tissue. A second animal (young: 5 years) had two foci in the left lower lobe, representing about 10% of the lung tissue (Fig. 2A). The consolidated lung tissue was well-circumscribed, red-purple, level, and less buoyant than normal. The other organs in these two macaques, as well as the respiratory tract and other organs of the other two animals were normal.

Virus replication was assessed by RT-qPCR on day 4 p.i. in tissues from the respiratory, digestive, urinary, and cardiovascular tracts, from endocrine and central nervous systems, as well as from various lymphoid tissues. Virus replication was primarily restricted to the respiratory tract (nasal cavity, trachea, bronchi and lung lobes) with highest levels of SARS-CoV-2 RNA in lungs (Fig. 1C). Interestingly, in three out of four animals, SARS-CoV-2 RNA was also detected in ileum and tracheo-bronchial lymph nodes (Fig. 1C).

The main histological lesion in the consolidated pulmonary tissues of both the young and aged animals involved the alveoli and bronchioles and consisted of areas with acute or slightly depressed areas in the lungs, representing less than 5% of the lung tissue (Table 1). Similar to SARS-CoV-2 infection in both young and aged animals, on day 4 p.i., MERS-CoV RNA was primarily detected in the respiratory tract of inoculated animals (Fig. 3C). Infectious virus titers were comparable to SARS-CoV-2, but lower compared to SARS-CoV infection of young macaques (Table 1). In addition, MERS-CoV RNA was detected in rectal swabs on days 2 and 3 p.i.

At autopsy of four macaques at day 4 p.i., three animals had foci of pulmonary consolidation, characterized by slightly depressed areas in the lungs, representing less than 5% of the lung tissue (Table 1). Similar to SARS-CoV-2 infection in both young and aged animals, on day 4 p.i., MERS-CoV RNA was primarily detected in the respiratory tract of inoculated animals (Fig. 3C). Infectious virus titers were comparable to SARS-CoV-2, but lower compared to SARS-CoV infection of young macaques (Table 1). In addition, MERS-CoV RNA was detected in the spleen (Table 1).

Consistent with the presence of virus in the lower respiratory tract at day 4 p.i., histopathological changes characteristic for DAD were observed in the lungs of inoculated animals (Fig. 3D). The alveolar septa were thickened owing
to infiltration of neutrophils and macrophages, and moderate type II pneumocyte hyperplasia and hypertrophy. In the alveolar lumina, there were elevated alveolar macrophages and some edema fluid containing fibrin and some neutrophils (Fig. 3D). Few syncytial cells were seen in the alveolar lumina. Interestingly, MERS-CoV antigen was not detected in tissues on day 4 p.i. in any part of the respiratory tract. We therefore sampled four young macaques at day 1 p.i. At this time we observed multifocal expression of viral antigen, predominantly in type II pneumocytes and occasionally in type I pneumocytes, bronchiolar and bronchial epithelial cells and some macrophages (Fig. 3D).

In summary, we inoculated young and aged cynomolgus macaques with a low passage clinical isolate of SARS-CoV-2, which resulted in productive infection in the absence of overt clinical signs. Recent studies in human cases have shown that symptomatic and asymptomatic cases can also shed virus (14, 15). Increased age did not affect disease outcome, but there was prolonged viral shedding in the upper respiratory tract of aged animals. Prolonged shedding has been observed in both SARS-CoV-2 and SARS-CoV patients (16, 17). Interestingly, SARS-CoV-2 shedding in our asymptomatic model, peaked early in the course of infection, similar to what is seen in symptomatic patients (16). Also, SARS-CoV-2 antigen was detected in ciliated epithelial cells of nasal mucosae at day 4 p.i., which was not seen for SARS-CoV (10) or MERS-CoV infections (this manuscript) in this animal model. Viral tropism for the nasal mucosa fits with efficient respiratory transmission, as has been seen for influenza A virus (18). This early peak in virus shedding for SARS-CoV-2 is similar to influenza virus shedding (19) and may explain why case detection and isolation may not be as effective for SARS-CoV-2 as it was for the control of SARS-CoV (20). SARS-CoV-2 was primarily detected in tissues of the respiratory tract, however SARS-CoV-2 RNA was also detectable in other tissues such as intestines, in line with a recent report (21). Similar results regarding viral shedding and tissue and cell tropism were recently also reported following SARS-CoV-2 inoculation in rhesus macaques. However, unlike in our model, SARS-CoV-2 infection in rhesus macaques does result in transient respiratory disease and weight loss (22, 23).

Two out of four animals had focsi of DAD on day 4 p.i. The colocalisation of SARS-CoV-2-antigen expression and DAD provides strong evidence that SARS-CoV-2 infection caused this lesion. The histological character of the DAD, including alveolar and bronchiolar epithelial necrosis, alveolar edema, hyaline membrane formation, and accumulation of neutrophils, macrophages and lymphocytes, corresponds with the limited pathological analyses of human COVID-19 cases (6, 7). In particular, the presence of syncytia in the lung lesions is characteristic of respiratory coronavirus infections. Whereas MERS-CoV primarily infects type II pneumocytes in cynomolgus macaques, both SARS-CoV and SARS-CoV-2 also infect type I pneumocytes. Injury to type I pneumocytes can result in pulmonary edema, and formation of hyaline membranes (24), which may explain why hyaline membrane formation is a hallmark for SARS and COVID-19 (7, 10), but not frequently reported for MERS (25, 26).

These data show that cynomolgus macaques are permissive to SARS-CoV-2 infection, shed virus for a prolonged period of time and display COVID-19-like disease. In this non-human primate model, SARS-CoV-2 replicates efficiently in respiratory epithelial cells throughout the respiratory tract, including nasal cavity, bronchi, bronchioles, and alveoli. Replication in the upper respiratory tract fits with efficient transmission between hosts, while replication in the lower respiratory tract fits with the development of lung disease. An in-depth comparison of infection with SARS-CoV, MERS-CoV and SARS-CoV-2 in this model may identify key pathways in the pathogenesis of these emerging viruses. This study provides a novel infection model which will be critical in the evaluation and licensure of preventive and therapeutic strategies against SARS-CoV-2 infection for use in humans, as well as evaluating the efficacy of repurposing species specific existing treatments, such as pegylated interferon (12).

REFERENCES AND NOTES


3. E. Mahase, Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ 368, m641 (2020). doi:10.1136/bmj.m641 Medline


This research is (partly) financed by TB, RF and BH are listed as an inventor on a patent application related to this study. Research was conducted in compliance with the Dutch Animal Welfare Act.


Acknowledgments

We thank L. de Meulder, A. van der Linden, I. Chestakova and F. van der Panne for technical assistance. V. Kap, D. Akkermans, V. Vaes, M. Sommers, F. Meijers for assistance with the animal studies. Funding: This research is (partly) financed by the NWO Stevin Prize awarded to M.K. by the Netherlands Organisation for Scientific Research (NWO). H2020 grant agreement 874735 - VEO to M.K., NIH/NIAIID contract HHSN272201400008C to R.F., and H2020 grant agreement 101003651 – MANCO to B.H. Author contributions: Conceptualization, B.R., T.K., R.F., M.R., Rds, M.F. B.H.; investigation, B.R., T.K., S.H., T.B., M.L., D.d.M., Y. Kap, D. Akkermans, V. Vaes, M. Sommers, F. Meijers; data curation, B.V., J.L., G. van Aerssen, J.v.d.B., N.O., D.S., P.v.R., L.L.; resources, B.H., C.D. E.V., B.V., J.L.; funding acquisition: S.H., B.H., R.F. and M.K. Animal welfare: Research was conducted in compliance with the Dutch Animal Welfare Act for the protection of animals used for scientific purposes (2014, implementing EU Directive 2010/63) and other relevant regulations. The licensed establishment where this research was conducted (Erasmus MC) has an approved OLAW Assurance # A5051-01. Research was conducted under a project license from the Dutch competent authority and the study protocol (#17-4312) was approved by the institutional Animal Welfare Body. Competing interests: TB, RF and BH are listed as an inventor on a patent application related to MERS-coronavirus diagnostics, therapy and vaccines. Other authors declare no competing interests. Data and materials availability: All data are available in the main text or the supplementary materials. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which
Fig. 1. Virus shedding and virus detection in organs of SARS-CoV-2 inoculated cynomolgus macaques. Viral RNA was detected in nasal (A) and throat (B) swabs and tissues (C) of SARS-CoV-2 infected animals by RT-qPCR. Samples from four animals (days 1-4) or two animals (days >4) per group were tested. The error bars represent the standard error of the mean. Virus was detected in tissues from two young, and two aged animals on day 4 by RT-qPCR. *= infectious virus was isolated.
Fig. 2. Characteristic pathological changes and virus antigen expression in the lungs of SARS-CoV-2-inoculated cynomolgus macaques. (A) Two foci of pulmonary consolidation in the left lower lung lobe (arrowheads). (B) Area of pneumonia (HE, bar indicates 0.5 cm). (C) Edema fluid in alveolar lumina (HE, bar indicates 25 μm). (D) Neutrophils, as well as erythrocytes, fibrin, and cell debris, in an alveolar lumen flooded by edema fluid (HE, bar indicates 10 μm). (E) Mononuclear cells, either type II pneumocytes or alveolar macrophages, in an alveolar lumen flooded by edema fluid (HE, bar indicates 10 μm). (F) Syncytium in an alveolar lumen (HE, 100X objective). Inset: Syncytium expresses keratin, indicating epithelial cell origin (IHC for pankeratin AE1/AE3, bar indicates 10 μm). (G) SARS-CoV-2 antigen expression is colocalized with areas of diffuse alveolar damage (IHC for SARS-CoV-nucleocapsid, bar indicates 50 μm). (H) Type I (flat) and type II (cuboidal) pneumocytes in affected lung tissue express SARS-CoV-2 antigen (IHC for SARS-CoV-nucleocapsid, bar indicates 25 μm). (I) Ciliated columnar epithelial cells of respiratory mucosa in nasal cavity express SARS-CoV-2 antigen (IHC for SARS-CoV-nucleocapsid, bar indicates 25 μm).
Fig. 3. Virus shedding and virus detection in organs of MERS-CoV inoculated cynomolgus macaques. Viral RNA was detected in nasal (A) and throat (B) swabs and tissues (C) of MERS-CoV infected animals by RT-qPCR. Samples from four animals per group were tested. The error bars represent the standard error of the mean. Virus was detected in tissues on day 4 by RT-qPCR. Histopathological changes (D: left picture) with hypertrophic and hyperplastic type II pneumocytes in the alveolar septa and increased numbers of alveolar macrophages in the alveolar lumina and virus antigen expression (right picture) in type II pneumocytes, bar indicates 50 μm.
Table 1. Comparative pathogenesis of SARS-CoV-2, MERS-CoV, and SARS-CoV infections in cynomolgus macaques.

<table>
<thead>
<tr>
<th>Virus</th>
<th>Age category</th>
<th>No.</th>
<th>Clinical signs</th>
<th>Maximum excretion from throat(^a)</th>
<th>Maximum excretion from nose(^a)</th>
<th>Viral titer in lung(^b)</th>
<th>Virus in extra-respiratory tissues</th>
<th>Pulmonary lesions at 4 days post inoculation</th>
<th>Leukocyte infiltration</th>
<th>Cell type tropism</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV</td>
<td>Young</td>
<td>4</td>
<td>No</td>
<td>10e3.5 TCID50eq</td>
<td>10e4.2 TCID50eq</td>
<td>10e6.5 TCID50eq</td>
<td>No</td>
<td>0 - 5</td>
<td>No</td>
<td>No</td>
<td>(10–12)</td>
</tr>
<tr>
<td>SARS-CoV</td>
<td>Aged</td>
<td>4</td>
<td>Yes</td>
<td>10e3.0 TCID50eq</td>
<td>10e3.0 TCID50eq</td>
<td>10e6.2 TCID50eq</td>
<td>Kidney</td>
<td>0 - 60</td>
<td>Yes</td>
<td>Yes</td>
<td>(10–12)</td>
</tr>
<tr>
<td>MERS-CoV</td>
<td>Young</td>
<td>4</td>
<td>No</td>
<td>10e5.3 TCID50eq</td>
<td>10e4.3 TCID50eq</td>
<td>10e4.4 TCID50eq</td>
<td>Spleen</td>
<td>0 - 5</td>
<td>No</td>
<td>Yes</td>
<td>This manuscript</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>Young</td>
<td>2</td>
<td>No</td>
<td>10e1.8 TCID50eq</td>
<td>10e2.4 TCID50eq</td>
<td>10e4.0 TCID50eq</td>
<td>ileum, colon, tonsil</td>
<td>0 – 10</td>
<td>Yes</td>
<td>Yes</td>
<td>This manuscript</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>Aged</td>
<td>2</td>
<td>No</td>
<td>10e2.9 TCID50eq</td>
<td>10e3.7 TCID50eq</td>
<td>10e3.1 TCID50eq</td>
<td>ileum, colon, tonsil</td>
<td>0 - 5</td>
<td>No</td>
<td>No</td>
<td>This manuscript</td>
</tr>
</tbody>
</table>

* TCID50eq per mL
* TCID50eq per gram tissue
Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Barry Rockx, Thijs Kuiken, Sander Herfst, Theo Bestebroer, Mart M. Lamers, Bas B. Oude Munnink, Dennis de Meulder, Geert van Amerongen, Judith van den Brand, Nisreen M. A. Okba, Debby Schipper, Peter van Run, Lonneke Leijten, Reina Sikkema, Ernst Verschoor, Babs Verstrepen, Willy Bogers, Jan Langemans, Christian Drosten, Martje Fentener van Vlissingen, Ron Fouchier, Rik de Swart, Marion Koopmans and Bart L. Haagmans

published online April 17, 2020